Executive summary

The U.S. has been among the most sought-after pharmaceutical markets in the world for decades; however, accessing this enormous market is not easy. Not only must entrants gain marketing approval from the Food and Drug Administration, they must also ensure access to patients by gaining prescriber and payer acceptance. Meeting the combined challenges of marketing approval, payer acceptance, assured reimbursement and access to patients is the result of a studied and deliberate approach to product development and launch. This studied approach is particularly important in rare disease product categories with low numbers of patients, high development costs and managed care plans focused on controlling spend.
<table>
<thead>
<tr>
<th>Introduction</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>A key global market</td>
<td>3</td>
</tr>
<tr>
<td>Product launch planning</td>
<td>5</td>
</tr>
<tr>
<td>Focus on payers</td>
<td>7</td>
</tr>
<tr>
<td>Ready, set, approved</td>
<td>8</td>
</tr>
<tr>
<td>About the authors</td>
<td>10</td>
</tr>
</tbody>
</table>
Introduction

The United States (U.S.) has been among the largest pharmaceutical markets in the world for decades. The Affordable Care Act (Obamacare) added significant new opportunities by expanding healthcare coverage to millions of individuals who could previously not obtain or could not afford health insurance. The dramatic jump in the number of covered lives increases the potential benefits for companies launching new therapies in the U.S.

Even as the U.S. expands its pharma market, it continues to maintain some of the highest barriers to entry, particularly for smaller healthcare companies. A few years ago, product marketing approval from the Food and Drug Administration (FDA) was the final step in an arduous healthcare research and development program. Today, FDA marketing approval is only another mandatory milestone in a thoroughly researched and well-designed product launch. A thoughtful and deliberate approach to a product launch is particularly important in the rare disease and orphan drug area in which patient numbers are low, development costs are high and managed care plans are focused on spending.

The ultimate goal is commercial acceptance in a market that is directed largely by payers and benefit managers who ultimately control patient access to new therapies. Meeting the challenges of payer acceptance, assured reimbursement and reasonable patient access requires a studied and considered product launch strategy. Strategy begins long before a new product is approved and continues long after distribution has begun. This insight brief will explore the structured product launch of Hemangeol®, a novel, orphan treatment for infantile hemangioma. The 120-day integrated launch program that we will discuss was designed and implemented in a partnership with Pierre Fabre Pharmaceuticals Inc., a European healthcare provider with limited experience in the U.S. market, and industry services provider, Quintiles to successfully introduce a new agent into this complex, dynamic and vital marketplace.

A key global market

The United States is among the largest therapeutic marketplaces in the world, a commercial target that no serious healthcare firm can afford to ignore. Overcoming significant barriers to entry opens way to a regulatory and reimbursement system that can provide unmatched access to treatment and commercial rewards. As of June 2015, the U.S. spent $339 billion yearly in moving annual dollars with 11.8 percent annual growth in sales according to IMS Health and Citi. IMS Health reported that new brand spending grew by $19.8 billion between June 2014 and June 2015. No other healthcare market on earth offers greater rewards.
At the same time, a strictly codified and transparent regulatory regime allows manufacturers to provide patients with safe and effective products in an open marketplace that protects intellectual property. Both the private and public sectors have demonstrated decades of support for the research and development communities and a motivated workforce that allows companies to better leverage investments for future growth and continuing R&D. In addition, while FDA regulators generally require products that are approved to be tested in U.S. populations, they welcome new and innovative therapeutics that have been developed elsewhere to support the goal of providing the best healthcare in the world.

Reaping those rewards is neither easy nor assured. The most obvious challenge is obtaining FDA marketing approval, a process that is clearly laid out in rules, regulations, procedures and scientific advices to industry. But, FDA approval does not ensure commercial success. Payers largely determine patient access to new agents and increasing attention to outcomes, not simply to treatment. This shift is particularly clear in the rare disease and orphan drug market, an area of growing interest for healthcare.

Clinicians may see the therapeutic value of a new product and prescribe it eagerly, but whether that prescription is approved and reimbursed is an independent decision made by more than 3,000 governmental and commercial sectors, payers and pharmacy benefit managers (PBMs). Payers want to see evidence that a new agent offers a measurable improvement in clinical efficacy, cost effectiveness, quality of life or defined outcomes compared to existing therapies. If there are no existing approved therapies, as was the case with infantile hemangioma before Pierre Fabre developed Hemangeo®, payers expect to see improvements compared to the current standard of care, including surgery or off-label use of agents approved for other indications.

The challenge in the U.S. is to demonstrate that a new agent, which is almost certainly more expensive than the current standard of care, represents a significant improvement in outcomes, overall costs for treatment or other factors that justify the additional expenditures for a new product. In essence, sponsors must demonstrate that an agent is safe and effective to obtain FDA approval, then demonstrate that it is more effective or more cost-effective than the current standard of care to gain payer approval.

---

Gaining access in the U.S.

**Key factors:**

- Knowledge, communication and collaboration are necessary ingredients
- Survey market landscape and prepare the market
- Identify appropriate business partners to help build out the infrastructure and fill the gaps
- Conduct additional market research to adapt the business model to the U.S. market dynamics
- Identify the business model to meet distribution needs
- Brand the corporate name with payers and healthcare providers
- Build KOL advocacy to establish disease and clinical profile
- Participate in prelaunch congresses and society meetings
- Develop patient support groups and foundations
**Product launch planning**

Infantile hemangioma is a vascular neoplasm, often called a strawberry birthmark, and it is estimated that it affects about 30,000 - 40,000 children yearly. And while most hemangiomas are benign, up to 12 percent of affected children require systemic therapy due to the location and severity of their hemangiomas. Hemangiomas that are rapidly proliferating can cause functional impairment, especially when the lesions are located in areas that affect hearing, vision or breathing. Rapid proliferation can be especially threatening for infants in the first few months of life.

The conventional treatment for infantile hemangioma is watch-and-wait with surgical intervention as needed. Hemangeol® is now the first agent to be approved by the FDA to treat infantile hemangioma. Interlesional steroids, propranolol and topical solutions have been used off-label for many years. Hemangiomas usually involute after several years, but even lesions that did not cause functional impairment can leave permanent tissue damage leading to physical and psychosocial scarring.

U.S. payers traditionally see drugs and biologic agents as cost drivers. The reality is that new agents can be cost savers compared to the existing standard of care. The challenge is to help payers recognize and understand that investing in a new therapeutic agent today can save significantly more on longer term therapy with less effective agents, surgery or other medical intervention and improved quality of life for patients and their families.

Commercial success in the U.S. market depends on three key factors that are controlled largely by payers. The new agent must:

- find a place on payer and PBM formularies
- avoid or minimize utilization controls such as prior approval or step therapy requirements that discourage prescribing
- be placed on payment tier that ensures patients can afford the product and are willing to accept the required copay

Building access for patient coverage in managed care is a structured, four step process. The first step is market research to understand the payer environment prior to FDA approval. The second step is establishing an advantageous formulary position that allows easy and affordable access to the drug after approval.

The third step is to analyze initial business to ensure that coverage is maximized to provide access to a sufficient number of patients to ensure commercial success. The final step is to develop patient programs, medication guides and caregiver education materials to enhance adherence and proper use of the medication to maximize outcomes. Each of these four steps must be adjusted to reflect the disease state, the patient population, the existing standard of care, awareness of the disease, attitudes toward the disease and commercial factors such as potential competition, pricing, distribution and formulary placement.
Pierre Fabre Pharmaceuticals Inc. and Quintiles invested more than two years in prelaunch planning, starting well before FDA approval of Hemangeol®. They analyzed the potential market and created a detailed 120-day product launch plan. The initial steps included surveys designed to gauge how managed care organizations, prescribers, payers, parents and regulators would likely view this novel product, assess the general level of knowledge about the condition and identify appropriate business partners to help build out the infrastructure needed to launch a new product.

One of the most important considerations was the size of Pierre Fabre itself. An international healthcare provider based in France, Pierre Fabre Pharmaceuticals Inc. launched the U.S. campaign for Hemangeol® a new division employee. It was important to establish the corporate identity with payers and healthcare providers. Creating a unique identity in the marketplace also enabled the company to identify the key opinion leaders (KOLs) in infantile hemangioma and work with them to establish an appropriate disease and clinical profile. Hemangeol® was discovered in Bordeaux, France, and the clinical development in France was eventually connected to the U.S. KOLs once the clinical trials were established in the U.S.

As clinical trials progressed, the KOLs presented results at clinical congresses and medical society events. This active participation in prelaunch scientific events helped to build awareness of both infantile hemangioma and emerging clinical data supporting the drug candidate that became known as Hemangeol®. The company also pursued opportunities to engage patient advocacy groups, helping them to understand the disease, its potential implications for infants and parents and the potential improvements to treatment and quality of life that an approved drug could bring.

The company’s small U.S. footprint also helped to guide decisions on distribution and sales. A limited distribution network using specialty pharmacies made sense, given the small patient numbers and the scattered geography of the market, as well as its getting classified as an orphan disease by the FDA. Pierre Fabre Pharmaceuticals Inc. wanted to ensure a high-touch delivery model to help educate caregivers with additional resources to manage infantile hemangioma. The small, geographically scattered patient population suggested a shared account management team for better access to payers, as it was a small rare disease product. Shared account management allowed a new-to-market company to leverage the established reputation of Quintiles’ national accounts team.
Focus on payers

The key consideration in developing KOLs, working with advocacy groups and creating the sales and distribution strategy was creating awareness among various stakeholders. Like many rare diseases, infantile hemangioma was not on their institutional or personal radar.

Early payer contacts, before Hemangeol® was approved, focused on disease awareness. Market research showed that 90 percent of physicians took a watch-and-wait approach to the condition. KOLs understood the importance of treating infantile hemangioma. The healthcare providers, based on their past training and education, were conservative in their approach. This resulted in seven out of ten children having the likelihood of permanent scarring or tissue distortion that could affect their quality of life, their physical and psychosocial functioning and their utilization of healthcare services.

The key to getting appropriate treatment is to get the product on formulary so providers can write prescriptions without hindrance and patients or caregivers can gain access. Providers can write a prescription for any product that is approved by the FDA, but gaining coverage for a prescription for a non-formulary product reimbursed by health plans can be a discouraging, bureaucratic process.

KOLs can help identify the kind of information health plan Pharmacy and Therapeutics (P&T) Committees are likely to request in their consideration of a new drug. P&T decisions are crucial in whether a new agent is placed on formulary and what restrictions may be placed on its use. Utilization management tools such as prior authorization, step therapy or requirements that patients first fail another treatment can discourage many physicians from writing a prescription in the first place.

Pricing and tier placement are equally important. Managed care is fast becoming the dominant payer structure for both governmental payers (Medicare, Medicaid, Veterans Administration, and Department of Defense) and commercial payers. Payers must pay attention to price as well as to clinical and quality of life improvements a new drug can bring. Only when payers understand the value that a new product can bring will they ease or eliminate prescribing barriers and place it on a copay tier that is acceptable and affordable for patients and caregivers.
Another key part of the 120-day launch plan is ensuring that launch materials are ready the day the new product is approved. In addition to pre-launch work, making the case for early and accessible formulary placement, the manufacturer must ensure the new product has its unique ten-digit NDC (National Drug Code) number loaded in their systems. All relevant materials are loaded by First DataBank and other compendia that provide drug information to prescribers and payers. If the compendia do not have complete and accurate information on a new therapeutic, it cannot be adjudicated and reimbursed properly.

Once compendia files are loaded, we must check with payers immediately after launch to ensure information is not just loaded, but loaded correctly. Any compendia errors or data transmission problems will slow initial uptake.

It may also be helpful to launch a patient assistance program when the product is launched. A high copay could block access for many parents while an easy-to-navigate patient assistance program can boost utilization and create good will among advocacy groups and prescribers.

Treatment guidelines are another important issue. Treatment recommendations at the time of approval are expert recommendations. It can be easy for payers to seek out the opinion of another, less well-informed expert to justify not adding a new agent on formulary or placing the product in an upper tier with a high copay to discourage utilization. Helping KOLs coalesce around a new drug, encouraging them to amass clinical data on usage and outcomes, can encourage the development of clinical guidelines to replace expert opinion. Once treatment guidelines are in place, KOLs, advocacy groups, prescribers and the manufacturer are in a stronger position to push for more favorable tier placement to increase patient access and utilization.
References

1. IMS Health, August 2015, Pharmaceutical trends, issues and outlook

2. Citi, September 2015, IMS Monthly Prescription Trends & Charts
About the authors

James (Jim) Anderson
Senior Director and Head of Reimbursement, Access & Distribution Solutions

As head of Reimbursement, Access & Distribution Solutions (RADS) at Quintiles, Anderson currently manages a team of RADS specialists in managed care and trade, which has access to more than 85 percent of managed lives in the United States.

With more than 30 years of commercial experience in the pharmaceutical and medical device markets, Anderson has held a variety of increasingly senior sales roles within the industry, including district manager, national accounts manager, regional director and national sales director. Throughout his career, Anderson has built several successful managed markets and reimbursement teams as well as directed trade and customer service groups for both pharmaceutical and device companies. His additional experience includes sales operations, contract administration and out-sourced manufacturing. Prior to joining Quintiles, Anderson was the chief operating officer of an ophthalmic pharmaceutical start-up company in the glaucoma surgery market.

Anderson graduated with a bachelor’s degree in finance from Fort Hays State University, in Hays, Kansas.

Joseph Bonaccorso
Vice President, Dermo-Pediatrics & Oncology, Pierre Fabre Pharmaceuticals Inc.

Joe has 30 years’ experience and is currently Head of Pierre Fabre Pharmaceuticals Inc. Joe has led market entry for Pierre Fabre into the U.S. by creating Pierre Fabre Pharmaceuticals Inc., which includes Dermo-Pediatric and Oncology business units.